Florham Park, NJ, April 7th, 2021
Xiromed LLC, the New Jersey-based generic division of Insud Pharmaceuticals, today announced the launch of Chlordiazepoxide HCl and Clidinium Bromide Capsules, generic to Librax®.
“The launch of Chlordiazepoxide HCl and Clidinium Bromide Capsules is the latest addition to Xiromed’s robust portfolio of generic pharmaceutical products and demonstrates our commitment to offering affordable generics to the US market,” commented Xiromed CEO, Narasimhan Mani.
Annual market sales for Librax® Capsules and its generics for the twelve month period ending February, 2021 were $100.5 million, according to IQVIA™.
Xiromed LLC, located in Florham Park, NJ, is the US generic division of Insud Pharma, S.L., a global pharmaceutical group headquartered in Madrid, Spain. Xiromed is focused on developing and commercializing high quality generic pharmaceutical products for the US market. In addition to its commercial portfolio of generics available in the US, Xiromed has a robust development portfolio of generic pharmaceutical products in various stages of development, including injectable, inhalation and complex generic products. Learn more at http://www.xiromed.com/usa/